Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
SynopsisP

Varicella vaccine cost-effective: US study

Pauline Comeau
CMAJ November 09, 2004 171 (10) 1161-1161-a; DOI: https://doi.org/10.1503/cmaj.1041610
Pauline Comeau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

A new US study concluding that chickenpox vaccination programs can save millions in direct medical costs comes at a time when more Canadian jurisdictions are adding varicella to their list of covered immunizations.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure. Varicella vaccination saved almost $100 million by reducing hospital admission rates. Photo by: E. Wooltorton

The study, published in the September issue of Pediatrics (114[3]:786-92), examined hospitalization and financial charge data from 1993–2001. In 1995, live attenuated varicella vaccine was universally recommended for children. The study concludes that hospital admission rates for chickenpox and related complications dropped 74% between 1995 and 2001, and saved almost $100 million. The current vaccination rate in the US has climbed to 85% for children aged 19–35 months (44 states have made it mandatory for school enrolment).

“Not only children but adolescents and adults appear to have benefited from lower hospitalization rates for chickenpox in the vaccine era,” Dr. Matthew Davis, lead author of the study and a pediatrician at the University of Michigan's C.S. Mott Children's Hospital, told CMAJ.

The study found the US public insurance program (Medicaid) benefited the most from reduced hospitalization rates and charges.

The results should quell the scepticism of some parents and physicians about whether a varicella vaccination program is worthwhile, says Davis.

Dr. Arlene King, director of Immunization and Respiratory Infection at Health Canada, calls the conclusions striking. “We knew that varicella immunizations were cost effective if you included indirect costs,” she says, “but it exceeds our expectations insofar as this looks to be cost effective even when you just consider the health care costs, which is really terrific news. Health care systems like to see the impact on their expenditures.”

Canadian jurisdictions are working toward coast-to-coast varicella vaccine coverage by 2005. This year Ottawa established a $300-million, 3-year national immunization program.

Only Newfoundland and Labrador, BC and Quebec have not yet announced varicella vaccine coverage, but programs are pending. — Pauline Comeau, Ottawa

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 171 (10)
CMAJ
Vol. 171, Issue 10
9 Nov 2004
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Varicella vaccine cost-effective: US study
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Varicella vaccine cost-effective: US study
Pauline Comeau
CMAJ Nov 2004, 171 (10) 1161-1161-a; DOI: 10.1503/cmaj.1041610

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Varicella vaccine cost-effective: US study
Pauline Comeau
CMAJ Nov 2004, 171 (10) 1161-1161-a; DOI: 10.1503/cmaj.1041610
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Drugs: immunologic

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire